Search This Blog

Thursday, February 9, 2023

CDC Director Defends Mask Mandates After New Study Shows Masking Has Little Effect

 by Zachary Steiber via The Epoch Times (emphasis ours),

The director of the Centers for Disease Control and Prevention (CDC) on Feb. 8 defended her agency’s promotion of masking after a new study found that protective masks had little effect on the spread of respiratory viruses such as COVID-19.

The Cochrane review analyzed randomized controlled studies, considered the gold standard by U.S. officials and others, but limitations undermined the conclusions, according to CDC Director Dr. Rochelle Walensky.

One of the limitations of that study, in addition to the fact that it included randomized trials from before COVID-19, is that it stated in the study that people actually had limited update of using masks,” Walensky said during a hearing in Washington. “Of course, randomized trials that look at mask use by people who aren’t wearing them are going to have limited utility.

The CDC imposed mask mandates on public transportation users, including plane passengers, and on children in Head Start programs as young as 2, contradicting policies from other countries that left younger children maskless, if mandates were imposed at all.

The agency also repeatedly recommended that children, teachers, and others in schools wear masks, as well as people in common settings, such as grocery stores.

Multiple members of Congress pressed Walensky on the Cochrane review, which concluded that the available evidence shows a lack of effect in mask wearing against the spread of influenza or flu-like illnesses.

“While acknowledging the limited data pool, it found no clear sign of a reduction in transmission when using either medical or surgical masks,” Rep. Cathy McMorris Rodgers (R-Wash.) said. “Yet today, CDC still recommends masks in schools for all ages, even though the emotional, mental, physical, and educational toll masking has had on our kids is widely recognized.”

Walensky told Rodgers, “You actually have to wear a mask for it to work.

The CDC’s mandates and guidance on masks relied on cohort studies, Walensky said.

That included a non-peer-reviewed study that the agency published in its quasi-journal that compared the incidence of COVID-19 case clusters in schools located in districts with mask mandates with schools in districts without forced masking. Only two Arizona counties were studied.

A follow-up study that expanded on the number of districts involved and the time frame found that there was no link between school masking and COVID-19 cases.

The CDC also cites other studies in a scientific brief on the subject, including a randomized controlled trial in Bangladesh that found that masking had little effect on COVID-19 spread and a Chinese study of just 124 households.

Rep. Gary Palmer (R-Ala.) brought up the Cochrane study and said doctors have informed him that masks aren’t effective.

He asked Dr. Lawrence Tabak, acting director of the National Institutes of Health, whether that agency funded any trials examining mask efficacy in schools. Tabak said he wasn’t aware of any.

Walensky defended the lack of research.

So many studies demonstrated … that masks were working,” during the COVID-19 pandemic, she said, “that I’m not sure anybody would have proposed a clinical trial because in fact there weren’t equipoise.”

Apart from the Bangladesh trial, the two other randomized, clinical trials conducted in other countries provided little data to support masking against COVID-19.

Walensky also said this week that “now is not the moment” to drop mask mandates in schools. Many states have already lifted their mandates and others have recently announced that they’ll rescind their mandates.

Lockdowns

During the hearing, Walensky also defended the lockdowns imposed in the United States during the pandemic.

“I agree that we should do everything in our power not to have it happen [again],” she said, referring to school closures and other lockdown policies.

But she recounted how being a clinician in 2020, there was a morgue outside her hospital. When hospitals are overwhelmed and unable to take care of brain tumors and car accident victims, “extraordinary measures are necessary,” Walensky said.

“I do think when there are lockdowns, there’s decreased need for things like motor vehicle accident care,” she said, disagreeing with Rep. Neal Dunn (R-Fla.) on the issue.

When members pointed out that the COVID-19 vaccines don’t stop transmission, undercutting the rationale for vaccine mandates imposed by the Biden administration, Walensky pushed back, claiming that the vaccines prevent severe disease and death. It “doesn’t prevent transmission as well as it did for prior variants, but it does still prevent some,” Walensky said, referring to all vaccines as one type.

The CDC was consulted before the mandates were issued, she confirmed.

“What we have though is a modest prevention, like a 50 percent prevention, of risk of getting infected if you’re up to date on your vaccination, and that’s very important for frontline workers of all types to stay healthy, for children not to infect their grandparents that may be at risk,” said Dr. Robert Califf, commissioner of the Food and Drug Administration.

“If you’re up to date, your risk of dying is reduced by 80 percent.”

Califf was referring to the updated bivalent vaccines, for which there’s no clinical data half a year after the administration authorized them. The U.S. government and outside researchers have said in observational studies that the bivalents provide a subpar boost against infection and a better boost against severe illness.

https://www.zerohedge.com/political/cdc-director-defends-mask-mandates-after-new-study-shows-masking-has-little-effect

Youth cannabis vaping highest in medical marijuana states

 More U.S. high school seniors reported vaping cannabis in states where it is legal only for medical purposes than states where all adult use is permitted—a study finding that surprised the researchers.

About 27% of twelfth graders in medical marijuana states reported vaping cannabis compared to 19% in states that prohibited cannabis or allowed it for adult use, according to the Washington State University study.

"More than a quarter of our youth in medical states were vaping cannabis. That's a lot," said Christian Maynard, a WSU sociology Ph.D. student and first author of the study published in the journal Drug and Alcohol Dependence Reports. "We were expecting medical and adult use states would be more similar. Instead, we didn't find any statistical difference between prohibited and adult use states."

For this study, Maynard and his advising professor, WSU sociologist Jennifer Schwartz, analyzed responses from 3,770 high school seniors to the 2020 Monitoring the Future survey, a project which has been surveying U.S. youth since 1975.

The researchers also analyzed a subset of 556 participants who had also answered questions about access to cannabis vaping products and risk perceptions. They found that 62% of the high school seniors in medical marijuana states reported very easy access to cannabis vaping cartridges or "carts," and only 31% saw regular cannabis use as a great risk.

In both prohibited and adult use states, fewer high school seniors, 52%, reported easy access to cartridges. More also felt regular cannabis use was risky: 40% in prohibited states and 36% in adult use states.

The study could not identify exact reasons for the high rates of teen vaping in medical marijuana states, but Maynard suspected there may be a couple factors at play.

"It's possible the context of saying cannabis is for medical reasons is contributing to the fact that youth view it as less risky," said Maynard. "The difference in availability may also be that adult use  are providing legal cannabis to a wider range of people, which may in turn tamp down on the illegal market, and an adolescent can't go to a dispensary."

More research needs to be done to get to the reasons behind this difference, Maynard emphasized.

While cannabis and tobacco use among teens has been decreasing overall, vaping has bucked that trend. Among , cannabis vaping during the past 30 days made the second the biggest single-year jump in 2019 for any substance in the 45-year history of the Monitoring the Future study. It was only second to nicotine vaping.

Vaping remains popular even after crisis of related lung injuries in 2019 and 2020 that led to more than 2,000 hospitalizations including 68 deaths. Many of the cases were connected to cartridges sold outside of stores that contained Vitamin E, according to the Centers for Disease Control and Prevention.

The rise in cannabis  among teens highlights the need for parents and educators to help inform youth of the dangers, Maynard said.

"Like it or not, cannabis legalization seems to be happening across the country," he said. "It's very important to talk with adolescents. We know that at a younger age, when the brain is developing that cannabis is associated with harmful side effects. It's also not safe to buy  carts off the streets. You don't know what they're putting in those unregulated carts."

More information: Christian P Maynard et al, Cannabis vaping among high school seniors in adult-use, medical, and prohibited legal contexts, Drug and Alcohol Dependence Reports (2023). DOI: 10.1016/j.dadr.2023.100136


https://medicalxpress.com/news/2023-02-youth-cannabis-vaping-highest-medical.html

Study finds 41% of infant deaths associated with genetic diseases

 In a study appearing today in JAMA Network Open, Rady Children's Institute for Genomic Medicine (RCIGM) researchers found that the contribution of genetic diseases to infant deaths was higher than previously recognized. Of 112 infant deaths evaluated, single-locus (Mendelian) genetic diseases were found to be the most common antecedent of infant mortality and associated with 41% of the deaths.

Researchers also found that treatments predicted to positively impact outcomes were available for 30% of these genetic diseases. The implication of the study is that strategies for neonatal diagnosis have substantial potential to decrease mortality during the first year of life.

"At least 500 genetic diseases have effective treatments that can improve outcomes, and it seems that undiagnosed genetic diseases are a frequent cause of preventable deaths," said Stephen Kingsmore, MD, President & CEO of RCIGM. "Broad use of genomic sequencing during the first year of life could have much greater impact on infant mortality than was recognized hitherto."

The  was conducted at Rady Children's Hospital in San Diego and included 546 infants (112  [20.5%] and 434 infants [79.5%] with acute illness who survived) who underwent diagnostic whole-genome sequencing (WGS) between Jan. 2015 and Dec. 2020. Infants underwent WGS either premortem or postmortem with semiautomated phenotyping and diagnostic interpretation.

Among the findings:

  • Single-locus genetic disease were the most common identifiable cause of infant mortality, with 47 genetic diseases identified in 46 infants (41%).
  • 39 (83%) of these diseases had been previously reported to be associated with childhood mortality.
  • 28 death certificates (62%) for 45 of the 46 infants did not mention a genetic etiology.
  • Treatments that can improve outcomes were available for 14 (30%) of genetic diseases.
  • In five of seven infants in whom genetic diseases were identified postmortem, death might have been avoided had rapid, diagnostic WGS been performed at the time of symptom onset or intensive care unit admission.

"Prior etiologic studies of infant  are generally retrospective, based on electronic health record and  certificate review, and without genome information, leading to underdiagnosis of genetic diseases. In fact, prior studies show at least 30% of  have inaccuracies," said Christina Chambers, Ph.D., MPH, who co-led the study. "By implementing broad use of genome sequencing in newborns we might substantially reduce ."

To that end, in June 2022, RCIGM announced a novel program to advance and evaluate scalability of a diagnostic and precision medicine guidance tool called BeginNGS (pronounced "beginnings") to screen newborns for approximately 500  that have known  using rapid Whole Genome Sequencing (rWGS).

BeginNGS uses rWGS to diagnose and identify treatment options for genetic conditions before symptoms begin, an advancement over current pediatric uses of rWGS that focus mainly on children who are already critically ill.

Once a diagnosis is made, BeginNGS uses Genome-to-Treatment (GTRx), a tool that provides immediate treatment guidelines for physicians to help them understand genetic conditions and their available treatment options, which may include therapeutics, dietary changes, surgery, medical devices or other interventions.

More information: Reclassification of the Etiology of Infant Mortality With Whole-Genome Sequencing, JAMA Network Open (2023). DOI: 10.1001/jamanetworkopen.2022.54069


https://medicalxpress.com/news/2023-02-infant-deaths-genetic-diseases.html

Calorie restriction slows pace of aging in healthy adults

 In a first of its kind randomized controlled trial an international team of researchers led by the Butler Columbia Aging Center at the Columbia University Mailman School of Public Health shows that caloric restriction can slow the pace of aging in healthy adults. The CALERIE intervention slowed pace of aging measured from participants' blood DNA methylation using the algorithm DunedinPACE (Pace of Aging, Computed from the Epigenome). The intervention effect on DunedinPACE represented a 2-3 percent slowing in the pace of aging, which in other studies translates to a 10-15 percent reduction in mortality risk, an effect similar to a smoking cessation intervention. The results are published online in the journal Nature Aging.

"In worms, flies, and mice,  can slow  of aging and extend healthy lifespan" says senior author Daniel Belsky, Ph.D., associate professor of epidemiology at Columbia Mailman School and a scientist with Columbia's Butler Aging Center. "Our study aimed to test if calorie restriction also slows biological aging in humans."

The CALERIE Phase-2 randomized controlled trial is the first ever investigation of the effects of long-term calorie restriction in healthy, non-obese humans. The trial randomized 220 healthy men and women at three sites in the U. S. to a 25 percent calorie-restriction or normal diet for two years. CALERIE is an acronym for 'Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy'.

To measure biological aging in CALERIE Trial participants, Belsky's team analyzed  collected from trial participants at pre-intervention baseline and after 12- and 24-months of follow-up. "Humans live a long time," explained Belsky, "so it isn't practical to follow them until we see differences in aging-related disease or survival. Instead, we rely on biomarkers developed to measure the pace and progress of biological aging over the duration of the study." The team analyzed methylation marks on DNA extracted from white blood cells. DNA methylation marks are chemical tags on the DNA sequence that regulate the expression of genes and are known to change with aging.

In the primary analysis Belsky and colleagues focused on three measurements of the DNA methylation data, sometimes known as "epigenetic clocks". The first two, the PhenoAge and GrimAge clocks, estimate , or the chronological age at which a person's biology would appear "normal". These measures can be thought of as "odometers" that provide a static measure of how much aging a person has experienced. The third measure studied by the researchers was DunedinPACE, which estimates the pace of aging, or the rate of biological deterioration over time. DunedinPACE can be thought of as a "speedometer".

"In contrast to the results for DunedinPace, there were no effects of intervention on other epigenetic clocks," noted Calen Ryan, Ph.D., Research Scientist at Columbia's Butler Aging Center and co-lead author of the study. "The difference in results suggests that dynamic 'pace of aging' measures like DunedinPACE may be more sensitive to the effects of intervention than measures of static biological age."

Our study found evidence that calorie restriction slowed the pace of aging in humans" Ryan said. "But calorie restriction is probably not for everyone. Our findings are important because they provide evidence from a  that slowing human aging may be possible. They also give us a sense of the kinds of effects we might look for in trials of interventions that could appeal to more people, like intermittent fasting or time-restricted eating."

A follow-up of trial participants is now ongoing to determine if the intervention had long-term effects on healthy aging. In other studies, slower DunedinPACE is associated with reduced risk for heart disease, stroke, disability, and dementia. "Our study of the legacy effects of the CALERIE intervention will test if the short-term effects observed during the trial translated into longer-term reduction in aging-related chronic diseases or their ," says Sai Krupa Das, a senior scientist and CALERIE investigator who is leading the long-term follow up of CALERIE participants.

DunedinPACE was developed by Daniel Belsky and colleagues at Duke University and the University of Otago. To develop DunedinPACE, researchers analyzed data from the Dunedin Longitudinal Study, a landmark birth cohort study of human development and aging that follows 1000 individuals born in 1972-73 in Dunedin, New Zealand. Researchers first analyzed the rate of change in 19 biomarkers across 20 years of follow-up to derive a single composite measure of the Pace of Aging. Next, the researchers used machine-learning techniques to distill this 20-year Pace of Aging into a single-time-point DNA methylation blood test. The values of the DunedinPACE algorithm correspond to the years of biological aging experienced during a single calendar year, providing a measure of the pace of aging.

More information: Daniel Belsky, Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial, Nature Aging (2023). DOI: 10.1038/s43587-022-00357-ywww.nature.com/articles/s43587-022-00357-y


https://medicalxpress.com/news/2023-02-calorie-restriction-pace-aging-healthy.html

New method to promote bone growth

 DNA can help to stimulate bone healing in a localized and targeted manner, for example after a complicated fracture or after severe tissue loss following surgery. This has been demonstrated by researchers at Martin Luther University Halle-Wittenberg (MLU), the University of Leipzig, the University of Aveiro (Portugal) and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS in Halle. They have developed a new process in which they coat implant materials with a gene-activated biomaterial that induces stem cells to produce bone tissue. Their findings were published in the journal Advanced Healthcare Materials.

Bones are a fascinating example of the body's ability to regenerate. They are able to regain full functionality—even after a fracture—thanks to their ability to form new, resilient tissue at the fracture site. "However, when it comes to complicated fractures or major tissue loss, even a bone's self-healing power is insufficient," explains Professor Thomas Groth, head of the Biomedical Materials research group at MLU's Institute of Pharmacy.

"In such cases, implants are needed to stabilize the bone, replace parts of joints, or bridge larger defects with degradable materials." The success of such implants depends largely on how well they are incorporated into the bone. Increased efforts have been made in recent years to support this process by coating implants with bioactive materials to activate bone cells and mesenchymal .

Mesenchymal stem cells are capable of generating different types of tissue, however activating them to specifically regenerate bone can be particularly challenging. In such cases, an extracellular matrix plays a crucial role. "The tissue between the  is made up of collagens and chondroitin sulfate, among other things," explains Groth.

"It can be artificially replicated and applied to the surface of implants to make them bioactive." This ensures that implants are incorporated better and are less likely to be rejected by the body. Drugs and activators can also be added to the artificial extracellular matrix to stimulate bone growth. One such activator is the protein BMP-2, which is already being used in spinal fusions or to treat complicated, non-healing fractures. However, studies have shown that the high dose of BMP-2 needed can lead to uncontrolled  formation in the surrounding muscle as well as to other undesirable side effects.

The researchers from Halle, Leipzig and Aveiro are therefore proposing a procedure that stimulates stem cells in a more targeted way and causes significantly fewer side effects. One thing they are focusing on is enhancing the design of the extracellular matrix. They use a special layer-by-layer technology to apply the biomaterial to the implant. This enables them to control its composition, structure and properties at the nano level. "It is a sophisticated process which we have perfected at MLU in collaboration with Fraunhofer IMWS," explains Thomas Groth.

This design at the nano level is needed to functionalize the biomaterial; here they are leaning on the expertise of colleague Dr. Christian Wölk from Leipzig. Instead of incorporating large amounts of BMP-2 directly into the biofilm and risking an uncontrolled release, he packages DNA fragments into lipid nanoparticles that act as transport containers. Only after the  has been inserted does the DNA migrate into the cells of the bone tissue and stimulate them to produce BMP-2. This, in turn, activates the bone-forming stem cells.

"Mimicking the  as a thin-film surface coating and functionalizing it with nanoparticles is a milestone in pharmaceutical materials research," explains Thomas Groth. "DNA can be released in a targeted manner and limits the stimulation of tissue growth with respect to time and location, without causing undesirable side effects."

According to Groth, the method is also fundamentally suited for transporting mRNA and thus expands the possibilities of regenerative medicine—not only in the field of  formation, but also for other therapeutic applications.

More information: Catharina Husteden et al, Lipoplex‐Functionalized Thin‐Film Surface Coating Based on Extracellular Matrix Components as Local Gene Delivery System to Control Osteogenic Stem Cell Differentiation, Advanced Healthcare Materials (2022). DOI: 10.1002/adhm.202201978


https://medicalxpress.com/news/2023-02-method-bone-growth.html

Newly-discovered brain circuit 'could put the brakes on risky behaviors'

 A team of researchers in the College of Medicine at the Medical University of South Carolina (MUSC) has discovered a brain circuit that inhibits motivated behaviors. They report in Nature Communications that the circuit is located in a region of the brain called the thalamus. When active, it can prevent reward-seeking behavior in a preclinical model. In the same model, blocking, or inhibiting, the circuit leads to reward seeking even in high-risk contexts.

Importantly, administering opioids causes immediate and significant disruption of the circuit, resulting in even riskier behaviors. The findings from this study address an understudied area of addiction research and emphasize a new perspective for studying and treating addiction.

Behavior can be thought of as a car moving through an intersection after stopping at a traffic light. For the car to move forward, the brake must be released, and the gas pedal must be pressed. In the past, addiction research has largely focused on the gas pedal, identifying  and circuits that promote reward-seeking behavior in hazardous contexts. However, this approach fails to address a major component of addiction—the inability to stop risky behavior from happening in the first place.

Researchers at MUSC recognized the importance of identifying these behavior-braking circuits and wanted to know why they were faulty in addiction.

"We stop ourselves from behaving inappropriately or making risky decisions every day," said James Otis, Ph.D., assistant professor in the Department of Neuroscience at MUSC and senior author of the study. "We need to understand how existing circuits that normally stop risky behaviors become tweaked so that they're less effective."

To find a potential brake circuit, the researchers focused on a region of the brain called the thalamus, which is known to integrate environmental and internal information that guides feeding and reward seeking. They examined brain activity in a preclinical model of reward-seeking behavior using an advanced imaging method called two-photon microscopy. This cutting-edge technique allowed the team to identify individual brain cells that were inhibited during reward seeking, much like a brake that must be released to drive forward.

The researchers were then able to generate a circuit map thousands of times more precise than could have been achieved with standard imaging methods like MRI. When they artificially inhibited the circuit, they found that reward-seeking behavior continued even in simulated high-risk situations that would normally prevent the behavior from happening. The researchers had found their brake.

To address what could lead to a faulty brake system in the context of addiction, the team asked whether commonly abused drugs, such as opioids, could interfere with the circuit's function.

"We've known for a long time that opioid use and use of other drugs strongly affect a human's ability to say no, to not perform risky actions," said Otis. "After we found out that this circuit is really important for suppressing risky behaviors, we wondered if heroin, an opioid and common drug of abuse, could shut it down and induce a risky decision. And we found that that's absolutely the case."

While the researchers expected to find that opioids had an effect on the circuit in some form or another, the magnitude of the effect that they discovered was surprising.

"What was really interesting to me was that just one heroin injection could immediately lead to riskier decisions. We found that it's because heroin binds directly to opioid receptors in the circuit and shuts down this brake," said Otis.

Moving forward, the researchers aim to determine whether this finding holds true for other substances of abuse, such as alcohol. They are also conducting studies to determine why certain brain cells respond differently in the presence of opioids, with the hope of finding targets for future treatments for addiction.

"We really need therapeutics that target these brain circuits more specifically, rather than mimicking what the drugs of abuse do to a lesser degree," said Otis. "I think that's a poor way of treating addiction. And I think most addiction biologists would agree with that."

Overall, Otis believes that the study's findings provide both words of warning and hope for the future.

"Using drugs of abuse like heroin can immediately cause risky decisions," he said. "But by targeting these brain pathways that go offline because of drug use, we may be able to develop improved therapeutics that restore their ability to act as a brake on reckless ."

More information: Kelsey M. Vollmer et al, An opioid-gated thalamoaccumbal circuit for the suppression of reward seeking in mice, Nature Communications (2022). DOI: 10.1038/s41467-022-34517-w


https://medicalxpress.com/news/2023-02-newly-discovered-brain-circuit-risky-behaviors.html

Inhalable powder could protect lungs against COVID-19, flu viruses

 Researchers have developed an inhalable powder that could protect lungs and airways from viral invasion by reinforcing the body's own mucosal layer. The powder, called Spherical Hydrogel Inhalation for Enhanced Lung Defense, or SHIELD, reduced infection in both mouse and non-human primate models over a 24-hour period, and can be taken repeatedly without affecting normal lung function.

"The idea behind this work is simple—viruses have to penetrate the mucus in order to reach and infect the cells, so we've created an inhalable bioadhesive that combines with your own mucus to prevent viruses from getting to your lung cells," says Ke Cheng, corresponding author of the paper describing the work. "Mucus is the body's natural hydrogel barrier; we are just enhancing that barrier."

Cheng is the Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at North Carolina State University's College of Veterinary Medicine and a professor in the NC State/UNC-Chapel Hill Joint Department of Biomedical Engineering.

The inhalable powder microparticles are composed of gelatin and poly(acrylic acid) grafted with a non-toxic ester. When introduced to a moist environment—such as the  and lungs—the microparticles swell and adhere to the mucosal layer, increasing the "stickiness" of the mucus.

The effects are most potent during the first eight hours after inhalation. SHIELD biodegrades over a 48-hour period, and is completely cleared from the body.

In a , SHIELD blocked SARS-CoV-2 pseudovirus particles with 75% efficiency four hours after inhalation, which fell to 18% after 24 hours. The researchers found similar results when testing against pneumonia and H1N1 viruses.

In a non-human primate model of both the original and delta SARS-CoV-2 variants, SHIELD-treated subjects had reduced viral loads—from 50 to 300-fold less than control subjects—and none of the symptoms commonly associated with infection in primates, such as lung inflammation or fibrosis. Since primates do not exhibit the same symptoms of infection as humans, viral load is the standard marker used to determine exposure.

The researchers also looked at potential toxicity both in vitro and in vivo: 95% of  exposed to a high concentration (10 mg ml-1) of SHIELD remained healthy, and mice who were given daily doses for two weeks retained normal  and respiratory function.

"SHIELD is easier and safer to use than other physical barriers or anti-virus chemicals," Cheng says. "It works like an 'invisible mask' for people in situations where masking is difficult, for example during heavy exercise, while eating or drinking, or in close social interactions. People can also use SHIELD on top of physical masking to have better protection.

"But the beauty of SHIELD is that it isn't necessarily limited to protecting against COVID-19 or flu. We're looking at whether it could also be used to protect against things like allergens or even air pollution—anything that could potentially harm the lungs."

The study appears in Nature Materials.

More information: University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill & Raleigh, NC, USA, An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection, Nature Materials (2023). DOI: 10.1038/s41563-023-01475-7www.nature.com/articles/s41563-023-01475-7


https://medicalxpress.com/news/2023-02-inhalable-powder-lungs-covid-flu.html